Washington University to start trial in AD prevention
The Washington University School of Medicine in St. Louis announced plans for a placebo-controlled trial to evaluate Alzheimer's disease products from Roche (SIX:ROG; OTCQX:RHHBY) and Eli Lilly and Co. (NYSE:LLY) in 160 patients who have inherited mutations known to cause early onset AD. The study, slated to start early next year, will initially last for two years, after which it will be expanded and extended if one or more of the products is effective in slowing or stopping indicators of presymptomatic AD. The trial will include two products in Phase III testing: gantenerumab, a human mAb against beta amyloid from Roche, and solanezumab, an antibody binding to soluble beta amyloid from Lilly. The school also said the study could potentially include a beta-secretase inhibitor from Lilly that is in Phase II testing. Roche and Lilly will provide the products at no cost and will also provide supporting grants. ...